Amendments to the claims:

1. (Original) A cyclosporin analog of formula I or a pro-drug or a pharmaceutically acceptable salt thereof:

A---B---Sar-MeLeu-Val-MeLeu-Ala---U---MeLeu-MeLeu-MeVal
1 2 8

(I)

wherein

(i) A is of the formula:



(A1)

or



(A2)

wherein:

X is absent, -C1-C6 alkyl-, or -C3-C6 cycloalkyl-;

Y is selected from the group consisting of:

aryl, substituted aryl, heteroaryl, and substituted heteroaryl;

(ii) B is -αAbu-, -Val-, -Thr- or -Nva-; and

(iii) U is -(D)Ala-, -(D)Ser-, -[O-(2-hydroxyethyl)(D)Ser]-, -[O-(acyl)(D)Ser]- or -[O-(2-acyloxyethyl)(D)Ser]-.

2. (Original) A cyclosporin analog according to Claim 1 or a pro-drug or a pharmaceutically acceptable salt thereof, wherein in formula I, B is

-αAbu-, and U is -(D)Ala-.

3. (Original) A cyclosporin analog according to Claim 1 or a pro-drug or a pharmaceutically acceptable salt thereof, wherein in formula I:

(i) A is of the formula A1 or A2, wherein:

X is absent; and

Y is selected from the group consisting of:

aryl, substituted aryl, heteroaryl, and substituted heteroaryl;

(ii) B is -αAbu-; and

(iii) U is -(D)Ala-.

4. (Currently Amended) A cyclosporin analog according to Claim 1 or a pro-drug or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

Compound of formula (I), where A=A1, X is absent and Y = (2'-Me)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-F)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-CF_3)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2'-Br)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2'-Cl)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2'-OMe)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (3'-Cl)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-Cl)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (3'-Br)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-Br)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (3'-$COOCH_3$)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-$COOCH_3$)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2'- Naphthalene); B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-t-butyl)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (pentafluoro)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-AcO-)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-OCH_3)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (3', 4'-OMe_2)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2',5'-Me_2)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = Pyridine; B is –αAbu; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = Pyrrole; B is –αAbu; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (N-methyl) Pyrrole; B is –αAbu; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = Thiophene; B is –αAbu; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = Oxazole; B is –αAbu; and U is –(D)Ala-;

Compound of formula (I), where A=A2, X is absent and Y = (2'-Me)Ph; B is –αAbu; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (S)Ph; B is –αAbu; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (SO)Ph; B is –αAbu; and U is –(D)Ala-; and

Compound of formula (I), where A=A1, X is absent and Y = (SO_2)Ph; B is –αAbu; and U is –(D)Ala-.

Claims 5-10 (Withdrawn)

11. (Original) A pharmaceutical composition, said composition comprising at least one cyclosporin analog of formula I as claimed in Claim 1, said cyclosporin analog being present alone or in combination with a pharmaceutically acceptable carrier or excipient.

Claims 12-14 (Withdrawn)

15. (New) A cyclosporin analog of formula I or a pro-drug or a pharmaceutically acceptable salt thereof:

A---B---Sar-MeLeu-Val-MeLeu-Ala---U---MeLeu-MeLeu-MeVal
1 2 8

(I)

wherein

(i) A is of the formula:



(A1) (A2)

wherein:

X is absent, -C1-C6 alkyl-, or -C3-C6 cycloalkyl-;

Y is selected from the group consisting of:

(a) aryl substituted with one or more substituents independently selected from: CN, C_1-C_3-alkyl, C_3-C_6-alkoxy, C_1-C_6-alkoxy, C_3-C_6-alkoxy substituted with aryl, haloalkyl, thioalkoxy, amino, alkylamino, mercapto, nitro, carboxaldehyde, carboxy, alkoxycarbonyl, or carboxamide;

(b) heteroaryl; or

(c) substituted heteroaryl;

(ii) B is -αAbu-, -Val-, -Thr- or -Nva-; and

(iii) U is -(D)Ala-, -(D)Ser-, -[O-(2-hydroxyethyl)(D)Ser]-, -[O-(acyl)(D)Ser]- or -[O-(2-acyloxyethyl)(D)Ser]-.

16. (New) A cyclosporin analog of claim 15 defined by formula I, wherein X is absent and Y is phenyl substituted at the ortho position with a substituent independently selected from: CN, C_1-C_3-alkyl, C_3-C_6-alkoxy, C_1-C_6-alkoxy, C_3-C_6-alkoxy substituted with aryl, haloalkyl, thioalkoxy, amino, alkylamino, mercapto, nitro, carboxaldehyde, carboxy, alkoxycarbonyl, or carboxamide.

17. (New) A cyclosporin analog according to claim 15 or a pro-drug or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

Compound of formula (I), where A=A1, X is absent and Y = (2'-Me)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-CF_3)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2'-OMe)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (3'-$COOCH_3$)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-$COOCH_3$)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2'- Naphthalene); B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-t-butyl)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-AcO-)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-OCH_3)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (3', 4'-OMe_2)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2',5'-Me_2)Ph; B is –αAbu-; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = Pyridine; B is –αAbu; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = Pyrrole; B is –αAbu; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (N-methyl) Pyrrole; B is –αAbu; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = Thiophene; B is –αAbu; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = Oxazole; B is –αAbu; and U is –(D)Ala-;

Compound of formula (I), where A=A2, X is absent and Y = (2'-Me)Ph; B is –αAbu; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (S)Ph; B is –αAbu; and U is –(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (SO)Ph; B is –αAbu; and U is –(D)Ala-; and

Compound of formula (I), where A=A1, X is absent and Y = (SO_2)Ph; B is –αAbu; and U is –(D)Ala-.

18. (New) A cyclosporin analog of formula (I), where A=A1, X is absent and Y = (2'-Me)Ph; B is –αAbu–; and U is –(D)Ala–.

19. (New) A pharmaceutical composition, said composition comprising at least one cyclosporin analog of formula I as claimed in Claim 15, said cyclosporin analog being present alone or in combination with a pharmaceutically acceptable carrier or excipient.